Mobile Menu

Search Results

Search results for: inhibitor

LRRK2 inhibitors offer new hope for Parkinson’s disease

Cellular lysosomal degradative activity is key for healthy cell maintenance. As such, it is unsurprising that changes in the level […]

CSK1 inhibitor zaps leukaemic stem cells and could prevent relapse

Scientists have discovered a small molecule inhibitor that can suppress leukaemic stem cells while also protecting healthy stem cells from […]

An LRRK2 inhibitor shows promise as a Parkinson’s disease therapy

An experimental small molecule treatment for Parkinson’s disease can correct hallmarks of the condition in cells and animals. The study, […]

Reversing diabetes with a selective microRNA inhibitor

Researchers have designed a structure-specific microRNA inhibitor that selectively represses a microRNA family member, which may in turn reverse the […]

Genomics Week in Brief: Week ending 27th August

Check out the latest Genomics Week In Brief – full of intriguing news and research from the genomics space! Top […]

LSD1 promotes prostate cancer cell reprogramming through TP53 repression

Prostate cancers are generally treatable with positive survival outcomes. However, following common treatments such as androgen receptor inhibitors, some prostate […]

Genomics Week in Brief: Week ending 12th August

Check out the latest Genomics Week In Brief – full of intriguing news and research from the genomics space! Top […]

Brain tumour noncoding mutations are new targets for personalised medicine

Traditional cancer driver gene discovery has generally focussed on coding mutations, which can affect protein function and structure. Mutations in […]

Genomics Week in Brief: Week ending 5th August

Check out the latest Genomics Week In Brief – full of intriguing news and research from the genomics space! Top […]

Rebalancing immune hyperactivity in Down’s syndrome

Written by Charlotte Harrison, Science Writer  People with Down’s syndrome have chronic hyperactivation of interferon signalling, meaning they are at […]